GSK selling off a U.S. site; Sarepta founds a translational R&D lab;

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

@DamianFierce: Today's the FDA decision deadline for Keytruda's lung cancer app. Can't wait to see the TV ad. | Follow @DamianFierce

> Sarepta Therapeutics ($SRPT) signed a four-year agreement with researchers from Australia's Murdoch University to create the Sarepta Translational Laboratory, devoted to investigating applications for the company's technology beyond Duchenne muscular dystrophy. More

> GlaxoSmithKline ($GSK), in the process of downsizing and consolidating its U.S. operation, has put a 192,000-square-foot Pittsburgh site up for sale. News

> Ongoing bearishness on Wall Street isn't interrupting the steady stream of companies lining up to go public, Reuters reports, including a handful of biotechs. Story

Medical Device News

@FierceMedDev: Illumina expands in China with cancer Dx deal. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Study: Oraya radiation tech reduces need for eye injections in AMD patients. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: U.K. patient group demands government override Roche's Kadcyla patents. Article | Follow @EmilyWFierce

> Google sees independent startups as key to new Alphabet reorganization. Report

> NIH's BRAIN initiative, philanthropic Kavli Foundation provide $185M to study brain science. More

> Siemens nabs Abbott SVP to run healthcare in North America. Article

Pharma News

@FiercePharma: MSF campaigns at UN summit meeting to ease pressure on India's drug IP policies. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto. FiercePharmaMarketing story | Follow @CarlyHFierce

> Novartis targets Amgen's Enbrel with second biosimilar app. Story

> Ackman's fund takes a beating on Valeant pricing worries. Item

> FTC weighs in on Mylan case, saying generics tweaking may be anticompetitive. Article

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.